We further present evidence that targeting the activity of TLK1 as a druggable upstream activator of the NEK1>YAP1>CRPC pathway can be an important step in the management of PCa along with standard anti-androgen therapy in combination with a powerful inhibitor of TLK1 such as J54 [13] (rev. Here, TLK1 is linked to posterior cortical atrophy.